id
stringclasses 6
values | disease_basin
stringclasses 6
values | candidate_drug
stringclasses 6
values | trial_outcome_summary
stringclasses 6
values | failure_mode_evidence
stringclasses 6
values | candidate_subgroup_axes
stringclasses 6
values | responder_subgroup_signature
stringclasses 6
values | non_responder_signature
stringclasses 6
values | context_gates
stringclasses 6
values | failure_mode_class
stringclasses 6
values | salvage_hypothesis
stringclasses 6
values | verification_plan
stringclasses 6
values | notes
stringclasses 6
values | constraints
stringclasses 1
value | gold_checklist
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FCSC-001
|
post_viral_crash_basin
|
candidate immune modulator
|
Primary endpoint null; fatigue scale unchanged overall
|
Subgroup shows improved crash frequency
|
autonomic tone; PEM severity; viral reactivation markers
|
High PEM; high crash frequency; elevated reactivation markers
|
Low PEM; no crash pattern
|
pacing adherence; infection status
|
masked responder subgroup
|
Use in high-PEM subgroup with pacing protocol
|
Prospective enrichment; crash frequency endpoint
|
Signal masked by heterogeneity
|
Under 280 words.
|
subgroup+gate+class+plan
|
FCSC-002
|
metabolic_insulin_resistance_basin
|
candidate appetite agent
|
Weight loss modest overall; high dropout
|
Responder signal in high hunger phenotype
|
baseline hunger; sleep timing; GI tolerance
|
High hunger; stable sleep schedule; high adherence
|
Low hunger; irregular sleep; nausea prone
|
meal timing; dose titration
|
adherence-gated efficacy
|
Pair with meal timing protocol; slow titration
|
Stratify by hunger; track adherence and nausea
|
Context gate is tolerability
|
Under 280 words.
|
subgroup+gate+class+plan
|
FCSC-003
|
autoimmune_flare_basin
|
candidate cytokine inhibitor
|
Flare reduction not significant overall
|
Benefit only in high flare frequency subgroup
|
flare frequency; autoantibody load
|
Flares every 4 weeks; high autoantibody load
|
Flares rare; low autoantibody load
|
trigger seasonality; concurrent infections
|
frequency-gated efficacy
|
Enroll high-frequency patients; seasonal timing
|
Enriched trial; flare interval endpoint
|
Null hides subgroup benefit
|
Under 280 words.
|
subgroup+gate+class+plan
|
FCSC-004
|
hyperarousal_basin
|
candidate sleep agent
|
Sleep improves; daytime function worsens
|
Daytime impairment in slow metabolizers
|
metabolizer phenotype; baseline fatigue
|
Fast metabolizers; insomnia dominant
|
Slow metabolizers; baseline fatigue high
|
dose timing; occupational demands
|
toxicity in subgroup
|
Lower dose or earlier dosing in slow metabolizers
|
PK stratification; function endpoints
|
Context is metabolism and schedule
|
Under 280 words.
|
subgroup+gate+class+plan
|
FCSC-005
|
fibrotic_progression_basin
|
candidate antifibrotic
|
No significant slope change overall
|
Responder signal in early-stage imaging subgroup
|
disease stage; imaging pattern
|
Early-stage; mild imaging changes
|
Late-stage; advanced fibrosis
|
smoking exposure; adherence
|
stage-gated efficacy
|
Treat early-stage only with exposure removal
|
Stage-stratified trial; PFT slope
|
Early basin escapable
|
Under 280 words.
|
subgroup+gate+class+plan
|
FCSC-006
|
chronic_pain_sensitization_basin
|
candidate neuromodulator
|
Pain score improves; high discontinuation
|
Responders with high threat tone; nonresponders sedated
|
threat tone; sleep debt; comedication
|
High threat tone; low sedative burden
|
High sedative burden; falls risk
|
comedication; fall risk
|
contextual antagonism
|
Use only with sedative deprescribing
|
Run-in taper; falls endpoint
|
Context gate is sedation load
|
Under 280 words.
|
subgroup+gate+class+plan
|
What this dataset tests
When a drug failed overall
but contains a responder niche.
Required outputs
- responder subgroup signature
- non-responder signature
- context gates
- failure mode class
- salvage hypothesis
- verification plan
Use case
Second layer of the Therapeutic Niche Construction Kit.
- Downloads last month
- 692